<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Glaxosmithkline plc</title>
	<atom:link href="http://www.stockbloghub.com/tag/glaxosmithkline-plc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Still Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209</link>
		<comments>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209#comments</comments>
		<pubDate>Mon, 02 Apr 2012 17:37:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97209</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $8.25. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta in March 2011 for treating patients suffering from systemic lupus erythematosus (SLE) was a huge positive for Human Genome. The subsequent launch of the drug in Canada and several European nations, including Germany, Spain, Austria, Denmark, Finland, Hungary, Norway and Sweden is also encouraging. Benlysta, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Sales of the drug are growing, albeit slowly. Net sales of Benlysta improved 36.7% sequentially to $25.7 million in the final quarter of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/02/hgsi-human-genome-sciences-analyst-still-neutral-on-shares/97209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish</title>
		<link>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197</link>
		<comments>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88197</guid>
		<description><![CDATA[We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam’s third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss 36 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. The loss was, however, wider than the year-ago loss of $0.23 per share. Revenues for the reported quarter fell 24.9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746</link>
		<comments>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746#comments</comments>
		<pubDate>Wed, 30 Nov 2011 18:51:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87746</guid>
		<description><![CDATA[We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Isis Pharma’s lead pipeline candidate, Kynamro (mipomersen), is being developed for the treatment of familial hypercholesterolemia (FH). Isis Pharma has a collaboration agreement with Genzyme, a subsidiary of Sanofi-Aventis (SNY) for Kynamro. While the companies filed for EU approval of Kynamro in July, the US filing is scheduled to take place later this month. Acceptance of the US filing will trigger a $25 million milestone payment from Sanofi, most likely in early 2012. Isis Pharma and Sanofi ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Settles with Novartis</title>
		<link>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474</link>
		<comments>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:41:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87474</guid>
		<description><![CDATA[Mylan, Inc. (MYL) recently announced a settlement agreement with Novartis (NVS) relating to the generic version of Novartis’ bioidentical estrogen therapy Vivelle-Dot. As a result of the resolution, the lawsuit filed by Novartis will be dismissed and Mylan can launch a generic version of Vivelle-Dot on December 16, 2013, or earlier under certain circumstances. Mylan was the first to file an abbreviated new drug application (ANDA) with the US Food &#38; Drug Administration (FDA) to market the generic version of the drug. Accordingly, Mylan will enjoy an exclusivity period of 180 days when it will be the sole company to market the generic. The deal is subject to review by the US Department of Justice and the Federal Trade Commission. Earlier this month, Mylan entered into an agreement with Pfizer, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/myl-mylan-settles-with-novartis/87474/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Third Quarter Loss Deteriorates</title>
		<link>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313</link>
		<comments>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:01:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[FF]]></category>
		<category><![CDATA[First Opportunity Fund Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICS]]></category>
		<category><![CDATA[Morgan Stanley Insured California Municipal Securi]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86313</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) third quarter 2011 loss per share of 37 cents was wider than the Zacks Consensus loss Estimate of 33 cents as well as the year-ago loss of 29 cents per share. The wider loss was attributable to a lukewarm top-line performance as well as increased research and development (R&#38;D) expenses. Revenue at Theravance though up 21.3% over the prior year to $6.4 million was below the Zacks Consensus Estimate of $7 million. The Quarter in Detail Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with Astellas Pharma and GlaxoSmithKline plc (GSK). Theravance earned a royalty of $0.8 million on Vibativ sales from Astellas Pharma on net sales of $4.5 million. Vibativ, Theravance’s only commercialized drug, is an injectable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/thrx-theravance-third-quarter-loss-deteriorates/86313/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Riding High on Incivek Sales</title>
		<link>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343</link>
		<comments>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343#comments</comments>
		<pubDate>Wed, 02 Nov 2011 17:08:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86343</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted robust third quarter 2011 earnings (including stock-based compensation expense) of 56 cents per share, substantially above the Zacks Consensus Estimate of 19 cents and the year-ago loss of 99 cents. Increased revenues from the sale of hepatitis C virus (HCV) treatment, Incivek (telaprevir) helped record positive earnings. Revenues Riding on the strong sales of Incivek, which was launched in the second quarter of 2011, Vertex Pharma reported total revenue of $659.2 million, almost double the Zacks Consensus Estimate of $342 million and significantly above the year-ago figure of $23.8 million. Vertex Pharma’s third quarter revenues consisted of revenue earned from the sale of Incivek ($419.6 million), royalty revenue (up 4.5% to $8.5 million) and collaborative revenue (up 137.9% to $231.1 million). Collaborative revenue for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/vrtx-vertex-pharmaceuticals-riding-high-on-incivek-sales/86343/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug Presents Positive Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159</link>
		<comments>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159#comments</comments>
		<pubDate>Tue, 20 Sep 2011 18:50:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83159</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently presented positive data from a late-stage trial on its erectile dysfunction (ED) candidate, avanafil, at the 47th European Association for the Study of Diabetes Annual Meeting. The REVIEW-Diabetes study (TA-302), which enrolled 390 patients with type I and type II diabetes, demonstrated that patients receiving avanafil achieved significant improvement in erectile function. The data reported that patients dosed with avanafil showed improvement in the percentage of successful intercourse attempts, regardless of diabetes classification (type I or II), duration of diabetes, or baseline ED severity. Further, successful intercourse was achieved in some patients within 15 minutes of taking avanafil. Moreover, some patients experienced successful intercourse more than six hours after dosing. On average, the patients who enrolled for the study were 58 years old and had a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/vvus-vivus-erectile-dysfunction-drug-presents-positive-data/83159/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387</link>
		<comments>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:55:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82387</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In August 2011, Alkermes disclosed financial results for the first quarter of fiscal 2012. Alkermes suffered a net loss (excluding special items but including stock-based compensation expense) of $0.04 per share which compared favorably with the year-ago loss of $0.14 per share. The Zacks Consensus Estimate was a loss of $0.11 per share. The narrower year-over-year loss was attributable to higher revenues recorded in the reported quarter. The lead product at Alkermes is Risperdal Consta for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HGSI) Human Genome Sciences Analyst Maintains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747</link>
		<comments>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747#comments</comments>
		<pubDate>Mon, 22 Aug 2011 14:47:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81747</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Human Genome Sciences Inc. (HGSI) with a target price of $16.00. Human Genome, founded in 1992 and based in Rockville, Maryland, is a biopharmaceutical company. The US launch of Benlysta earlier in the year for treating patients suffering from systemic lupus erythematosus (SLE) is a huge positive for Human Genome. The subsequent approvals of the drug in the European Union (EU) and Canada are also encouraging. The drug, which has blockbuster potential, has been co-developed with GlaxoSmithKline (GSK). Benlysta is the first new lupus drug to be cleared in more than 50 years. Lupus is a potentially fatal autoimmune disease that is extremely difficult to treat. We believe that the approval of this potentially blockbuster candidate will drive Human Genome to profitability. Benlysta ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/22/hgsi-human-genome-sciences-analyst-maintains-neutral-recommendation/81747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ONXX) Onyx Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354</link>
		<comments>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354#comments</comments>
		<pubDate>Tue, 16 Aug 2011 18:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HCC]]></category>
		<category><![CDATA[HCC Insurance Holdings Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RCC]]></category>
		<category><![CDATA[Small Cap Premium & Dividend Income Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81354</guid>
		<description><![CDATA[We recently downgraded our recommendation on Onyx Pharmaceuticals, Inc. (ONXX) to Underperform from Neutral. We note that Onyx Pharma’s second quarter 2011 loss of 56 cents was well below expectations, mainly due to lower revenues and higher operating expenses. Despite improved sales of the company’s only marketed drug, Nexavar (sorafenib) for cancer, which came in at $245.7 million (up 4% year-over-year) during the quarter, Onyx Pharma’s revenues experienced a 1.2% decline, amounting to $68.0 million. Earnings were further reduced as a result of higher-than-expected operating expenses. While research and development (R&#38;D) spend went up 16.2% to $50.3 million, selling, general and administrative (SG&#38;A) expenses shot up 43.6% to $38.2 million. Increased expenses for the development of carfilzomib led to higher R&#38;D spend and an increase in employee headcount and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/onxx-onyx-analyst-downgrades-shares-to-underperform/81354/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Loss Narrowed Due To Lower Spend</title>
		<link>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947</link>
		<comments>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:24:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[OC]]></category>
		<category><![CDATA[Owens Corning]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80947</guid>
		<description><![CDATA[Vivus Inc. (VVUS) posted adjusted loss of 14 cents per share during the second quarter of fiscal 2011, in line with the Zacks Consensus Estimate. However, the loss was narrower than the year-ago loss of 27 cents per share. Lower operating expenses led to the narrower loss. The company did not record any revenues during the quarter, similar to the prior-year quarter. The Zacks Consensus Estimate for the quarter was $1 million. Quarterly Details During the quarter, research and development (R&#38;D) expenses decreased 18.7% to $11.0 million. Moreover, general and administrative expenses amounted to $5.3 million, reflecting a decline of 21.4%. Vivus experienced reduced R&#38;D spends during the reported quarter, as both Qnexa and avanafil have completed their clinical studies and have been filed for regulatory approval. Pipeline Update In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/vvus-vivus-loss-narrowed-due-to-lower-spend/80947/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International Beats Expectations &#8211; Ups View</title>
		<link>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862</link>
		<comments>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862#comments</comments>
		<pubDate>Mon, 08 Aug 2011 17:31:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Cogdell Spencer Inc.]]></category>
		<category><![CDATA[CSA]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80862</guid>
		<description><![CDATA[Valeant Pharmaceuticals International’s (VRX) second quarter 2011 earnings of 68 cents per share (excluding special items but including stock based compensation expense) beat the Zacks Consensus Estimate by 3 cents and the year-ago earnings by 8 cents per share. Bottom-line growth was driven by improved revenues. Adjusted diluted earnings, however, included an extraordinary gain of 6 cents from the sale of investment in Cephalon Inc. (CEPH). Revenues for the quarter were $609.4 million, marginally above the Zacks Consensus Estimate of $609 million and way ahead of the prior-year figure of $238.8 million. However, revenue included a one-time milestone payment of $40 million received from GlaxoSmithkline (GSK) related to the European launch of Trobalt (known as Potiga in the US). The improvement in revenues was primarily due to the September 2010 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/08/vrx-valeant-pharmaceuticals-international-beats-expectations-ups-view/80862/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Loss Reduced by Incivek</title>
		<link>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310</link>
		<comments>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings Inc.]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80310</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted second quarter 2011 loss (including stock-based compensation expense) of 82 cents per share, narrower than the Zacks Consensus Estimate of 93 cents and the year-ago loss of 83 cents. Increased revenues from the sale of hepatitis C virus (HCV) candidate, Incivek (telaprevir) helped reduce the loss. Revenues Riding on the strong sales of Incivek, which was launched during the quarter, total revenue soared 262% to $114.4 million, surpassing the Zacks Consensus Estimate of $54 million. Vertex Pharma’s first quarter revenues consisted of revenue earned from the sale of Incivek ($74.5 million), royalty revenue (up 37.8% to $10.0 million) and collaborative revenue (up 22.7% to $30.0 million). The company receives royalty from GlaxoSmithKline plc (GSK) on sales of Lexiva, a HIV protease inhibitor. Collaborative revenue consists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/vrtx-vertex-pharmaceuticals-loss-reduced-by-incivek/80310/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Earns FDA Approval for Generic</title>
		<link>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064</link>
		<comments>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064#comments</comments>
		<pubDate>Thu, 14 Jul 2011 18:48:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79064</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) delivered yet another positive momentum within a week, as the US Food and Drug Administration (FDA) approved fondaparinux sodium injection, the company’s bioequivalent generic version of Arixtra. The drug is currently marketed by GlaxoSmithKline plc (GSK) for preventing deep vein thrombosis (DVT) in adults who are undergoing hip fracture, hip replacement, or knee replacement surgery. Dr. Reddy’s received final approval from the FDA for the 2.5 mg/ 0.5 mL, 5.0 mg/ 0.4 mL, 7.5 mg/ 0.6 mL and 10 mg/ 0.8 mL doses of fondaparinux sodium injection. Dr. Reddy’s will be manufacturing the generic version under license using a patented process that is developed by Australia based Alchemia Limited. The current approval comes close on the heels of the US launch of the generic version of Novartis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/rdy-dr-reddys-laboratories-earns-fda-approval-for-generic/79064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658</link>
		<comments>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658#comments</comments>
		<pubDate>Fri, 08 Jul 2011 20:49:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78658</guid>
		<description><![CDATA[The legal tussle between Watson Pharmaceuticals Inc. (WPI) and Shire plc (SHPGY) intensified, with the latter filing a patent infringement case against Watson Pharma relating to Vyvanse. Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children aged 6 to 17 years and adults. The lawsuit comes in response to the  abbreviated new drug application (ANDA) filed by Watson Pharma with the US Food and Drug Administration (FDA) to market a generic version of Vyvanse. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing a patent infringement lawsuit, Shire has ensured a 30-month stay by the FDA. Consequently, the ANDA cannot be cleared by the regulatory body before August 23, 2014 or until a court ruling, whichever ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/08/wpi-watson-pharmaceuticals-entangled-in-legal-dispute/78658/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) Watson Pharmaceuticals Files More Abbreviated New Drug Applications</title>
		<link>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565</link>
		<comments>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:11:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77565</guid>
		<description><![CDATA[Watson Pharmaceuticals Inc. (WPI) recently announced that it has filed Abbreviated New Drug Applications (ANDA) with the US Food and Drug Administration (FDA) to market its generic version of GlaxoSmithKline plc’s (GSK) Avodart, indicated for the treatment of benign prostatic hyperplasia (BPH), and Novartis AG’s (NVS) Pataday 0.2%, indicated for the treatment of ocular itching that is associated with allergic conjunctivitis. In response, Glaxo filed a lawsuit against Watson Pharma in the United States District Court for the District of Delaware, and Alcon filed a lawsuit against Watson Pharma in the United States District Court for the Southern District of Indiana. Since both companies filed a suit within 30 days of the ANDA filing, the FDA cannot approve Watson Pharma’s generic Avodart and generic Pataday until November 17, 2013 and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/wpi-watson-pharmaceuticals-files-more-abbreviated-new-drug-applications/77565/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Seeks Label Expansion</title>
		<link>http://www.stockbloghub.com/2011/06/29/amgn-amgen-seeks-label-expansion/77769</link>
		<comments>http://www.stockbloghub.com/2011/06/29/amgn-amgen-seeks-label-expansion/77769#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:44:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77769</guid>
		<description><![CDATA[Amgen (AMGN) is looking to gain approval for additional indications of Xgeva. The company recently submitted a supplemental Biologics License Application (sBLA) seeking US Food and Drug Administration (FDA) approval for Xgeva (denosumab) for the reduction of the risk of developing bone metastases in men with castrate-resistant prostate cancer. Approval would make Xgeva the first therapy for the prevention or delay of the spread of cancer to the bone. Amgen’s application is based on data from a pivotal phase III study (&#8217;147) that was conducted in 1,432 men with castrate-resistant prostate cancer. Results from the ‘147 study showed that Xgeva improved median bone metastasis-free survival by 4.3 months compared to placebo. Xgeva sales should receive a major boost if Amgen succeeds in gaining approval for the prevention of bone metastases ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/amgn-amgen-seeks-label-expansion/77769/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Erectile Dysfunction Drug on Track</title>
		<link>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061</link>
		<comments>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061#comments</comments>
		<pubDate>Wed, 22 Jun 2011 17:02:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77061</guid>
		<description><![CDATA[Vivus Inc. (VVUS) recently reported positive results from a late-stage trial, REVIVE-RP (TA-303), on avanafil. The study evaluated the safety and efficacy of avanafil in the treatment of erectile dysfunction (ED) following bilateral, nerve-sparing, radical prostatectomy. The candidate met all the primary endpoints of the study, which included improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvement in the International Index of Erectile Function (IIEF). Additionally, the data showed that successful intercourse was achieved within 15 minutes of taking avanafil. On average, the patients who enrolled for the study were 58 years old, 19 months past their prostatectomy surgery dates and diagnosed with severe ED. The patients were given 100 mg or 200 mg of avanafil or placebo and were ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/vvus-vivus-erectile-dysfunction-drug-on-track/77061/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer&#8217;s Chantix Could Increase Heart Risk</title>
		<link>http://www.stockbloghub.com/2011/06/21/pfe-pfizers-chantix-could-increase-heart-risk/76842</link>
		<comments>http://www.stockbloghub.com/2011/06/21/pfe-pfizers-chantix-could-increase-heart-risk/76842#comments</comments>
		<pubDate>Tue, 21 Jun 2011 18:59:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76842</guid>
		<description><![CDATA[The US Food and Drug Administration (FDA) recently announced that Pfizer’s (PFE) smoking cessation aid Chantix (varenicline) could be linked with a small, increased risk of certain cardiovascular adverse events in patients with cardiovascular disease. The FDA’s announcement was based on a review of data from a randomized, double-blind, placebo-controlled study that was conducted to evaluate the safety and efficacy of Chantix for smoking cessation. The study was conducted with about 700 patients (35 – 75 years old). While Chantix was found to be effective in helping patients quit smoking and maintain abstinence for about a year, certain cardiovascular events (like angina pectoris, non fatal myocardial infarction, need for coronary revascularization, and new diagnosis of peripheral vascular disease or admission for a procedure for the treatment of peripheral vascular disease) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/21/pfe-pfizers-chantix-could-increase-heart-risk/76842/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) UCB Reports Data on Neupro</title>
		<link>http://www.stockbloghub.com/2011/06/19/eu-ucb-reports-data-on-neupro/76677</link>
		<comments>http://www.stockbloghub.com/2011/06/19/eu-ucb-reports-data-on-neupro/76677#comments</comments>
		<pubDate>Sun, 19 Jun 2011 17:34:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76677</guid>
		<description><![CDATA[UCB (UCBJF) recently reported results from post hoc analyses of its restless legs syndrome (RLS) treatment Neupro (rotigotine). The data were presented at the International Congress of Parkinson’s disease and Movement disorders. RLS is a neurological disorder that causes an uncontrollable urge to move the legs during periods of inactivity or rest. This disorder mainly occurs late in the evening and at night. However, epidemiological studies and UCB’s post hoc analysis suggested that patients may experience symptoms during the daytime also, leading to impairment of daytime functioning. The results from the post hoc analyses, which analyzed a six month study on Neupro in 458 patients, suggested patients dosed with Neupro (1 mg, 2 mg and 3 mg per 24 hours) experienced an improvement in daytime functioning and daytime symptoms compared ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/19/eu-ucb-reports-data-on-neupro/76677/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76322</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-on-shares-2/76322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253</link>
		<comments>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253#comments</comments>
		<pubDate>Tue, 14 Jun 2011 15:03:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[Neenah Paper Inc.]]></category>
		<category><![CDATA[NP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76253</guid>
		<description><![CDATA[We have maintained our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $24.00 per share following the announcement of first quarter 2011 financial results. Theravance’s first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate, but narrower than the year-ago loss of 35 cents per share. Revenues at Theravance increased 10% year over year to $6.3 million. An increase in royalty revenues from Vibativ sales in the reported quarter was attributable for both the jump in revenues and the narrower year-over-year loss per share. However, total revenue was below the Zacks Consensus Revenue Estimate of $7 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/thrx-theravance-analyst-maintains-neutral-rating-on-shares/76253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RDY) Dr. Reddy&#8217;s Laboratories Continues to Grow</title>
		<link>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172</link>
		<comments>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172#comments</comments>
		<pubDate>Fri, 03 Jun 2011 14:11:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Dreyfus Municipal Income Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74172</guid>
		<description><![CDATA[Dr. Reddy’s Laboratories (RDY) reported fiscal 2011 earnings per American Depositary Share (ADS) of $1.50 compared with 10 cents per ADS posted in fiscal 2010. Higher revenues and lower operating expenses helped boost earnings. Year at a Glance The company reported revenues of $1.7 billion during the fiscal year, reflecting a year-over-year increase of 6%. Dr. Reddy’s reports revenues under two segments – Global Generics and Pharmaceutical Services &#38; Active Ingredients (PSAI). Revenues at the Global Generics segment increased 10% to $1.2 billion. However, PSAI revenues declined 4% to $441 million during the year. While generics revenues increased 18% in North America, 19% in Russia and other CIS (Commonwealth of Independent States) markets, and 15% in India, they deteriorated 13% in Europe. In the European market, Germany was worst hit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/03/rdy-dr-reddys-laboratories-continues-to-grow/74172/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CRM) Salesforce-Toyota Make Allies</title>
		<link>http://www.stockbloghub.com/2011/05/24/crm-salesforce-toyota-make-allies/74822</link>
		<comments>http://www.stockbloghub.com/2011/05/24/crm-salesforce-toyota-make-allies/74822#comments</comments>
		<pubDate>Tue, 24 May 2011 22:34:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Internet Software & Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AKAM]]></category>
		<category><![CDATA[Akamai Technologies Inc.]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HOT]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[Savvis Inc]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SNE]]></category>
		<category><![CDATA[Sony Corporation]]></category>
		<category><![CDATA[Starwood Hotels & Resorts Worldwide Inc]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SVVS]]></category>
		<category><![CDATA[Symantec Corporation]]></category>
		<category><![CDATA[SYMC]]></category>
		<category><![CDATA[TM]]></category>
		<category><![CDATA[Toyota Motor Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74822</guid>
		<description><![CDATA[Salesforce.com Inc. (CRM) recently announced a strategic alliance with the multinational automobile manufacturer Toyota Motors Corp. (TM). Under the terms of the agreement, the companies will jointly develop a private social networking service, Toyota Friend, for Toyota owners. The service will be based on Salesforce.com’s Chatter application. Chatter is a collaboration application for enterprises, which enables users to connect and share information securely. Chatter also connects an organization’s employees with existing and prospective customers. Toyota Friend will feature a chat system, which will help customers in car maintenance through reminders akin to “tweets” from Twitter. Each car will have its own account on Toyota Friend, through which its owner will get text reminders for maintenance jobs like fuel refills or battery recharge. Interestingly, the car and its driver would be ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/24/crm-salesforce-toyota-make-allies/74822/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals Beats Earnings Estimates on Revenues</title>
		<link>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944</link>
		<comments>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944#comments</comments>
		<pubDate>Wed, 18 May 2011 15:22:13 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73944</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) first quarter 2011 earnings of 49 cents per share (excluding special items but including stock-based compensation expense) missed the Zacks Consensus Estimate by 2 cents and the year-ago earnings by 10 cents per share. Revenues for the quarter increased to $565 million, well above the Zacks Consensus Estimate of $517 million and the prior-year quarter’s revenue of $219.6 million. However, revenue included a one-time alliance and royalty revenue of $36 million related to the March 2011 out-licensing of product rights to Cloderm cream, a mid-potency steroid to Dr. Reddy&#8217;s Laboratories (RDY). Excluding the one-time payment, revenue was $529 million, which was still above both the Zacks Consensus Estimate and the prior-year revenue. Organically (excluding the impact of one-time revenues, acquisitions and foreign exchange), revenues grew 7% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/18/vrx-valeant-pharmaceuticals-beats-earnings-estimates-on-revenues/73944/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reported Loss Widens</title>
		<link>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669</link>
		<comments>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669#comments</comments>
		<pubDate>Mon, 09 May 2011 21:33:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73669</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents. Revenues came in at $21.1 million, well below the Zacks Consensus Estimate of $26 million. Lower revenues and higher operating expenses led to the wider first quarter 2011 loss. Quarter in Detail Revenues, which include license fees, milestone-related payments and other payments, declined 29.3% from the year-ago period during the first quarter of 2011. Isis Pharma earned a $750,000 milestone payment from OncoGenex (OGXI) on the initiation of a phase II study with OGX-427. First quarter revenues also included revenues recognized under the company’s collaboration agreement with GlaxoSmithKline (GSK). Isis Pharma could receive another ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Posts Wider Loss</title>
		<link>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436</link>
		<comments>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MAA]]></category>
		<category><![CDATA[Mid-America Apartment Communities Inc]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73436</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) posted first-quarter 2011 loss (including stock-based compensation expense) of $1.05 per share, in line with the Zacks Consensus Estimate, but wider than the year-ago loss of 80 cents. Increased expenses related to the potential launch of hepatitis C virus (HCV) candidate, Incivek (proposed US trade name for telaprevir), led to the higher loss. Revenues Revenues for the reported quarter increased 229% to $73.7 million, exceeding the Zacks Consensus Estimate of $25 million. First quarter revenues included a $50 million milestone payment received from Johnson &#38; Johnson (JNJ), on the acceptance of the Marketing Authorization Application (MAA) for Incivek in Europe. Vertex Pharma’s first quarter revenues consisted of royalty revenues (down 5.4% to $6.1 million) and collaborative revenues (up 321.9% to $67.6 million). The company receives royalty ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/vrtx-vertex-pharmaceuticals-posts-wider-loss-2/73436/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Reports Earnings In Line With Estimates</title>
		<link>http://www.stockbloghub.com/2011/05/04/thrx-theravance-reports-earnings-in-line-with-estimates/73180</link>
		<comments>http://www.stockbloghub.com/2011/05/04/thrx-theravance-reports-earnings-in-line-with-estimates/73180#comments</comments>
		<pubDate>Wed, 04 May 2011 16:46:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAP]]></category>
		<category><![CDATA[Market Vectors RVE Hard Assets Prod ETF]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73180</guid>
		<description><![CDATA[Theravance Inc.’s (THRX) first quarter 2011 loss per share of 28 cents was in line with the Zacks Consensus Estimate but narrower than the year-ago loss of 35 cents per share. Earnings improvement was driven by better top-line performance. Revenue at Theravance increased 10% over the prior year to $6.3 million due to higher royalty revenue from Vibativ sales in the reported quarter. Revenue was however below the Zacks Consensus Revenue Estimate of $7 million. The Quarter in Detail Revenues for the quarter primarily consisted of the amortization of deferred revenues received under the company’s collaborations with Astellas Pharma and GlaxoSmithKline plc (GSK). Theravance earned a royalty of $0.6 million on Vibativ sales from Astellas Pharma on net sales of $3.5 million. Vibativ is marketed by Astellas Pharma in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/04/thrx-theravance-reports-earnings-in-line-with-estimates/73180/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) GlaxoSmithKline and Valeant Pharmaceuticals Respond to CRL From FDA</title>
		<link>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377</link>
		<comments>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377#comments</comments>
		<pubDate>Tue, 26 Apr 2011 15:34:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72377</guid>
		<description><![CDATA[GlaxoSmithKline (GSK) and Valeant Pharmaceuticals (VRX) recently submitted a response to the Complete Response Letter (CRL) received from the US Food and Drug Administration (FDA) for their epilepsy candidate, ezogabine. The CRL, which was issued in Nov 2010, was for non-clinical reasons. We note that earlier, in August 2010, Glaxo and Valeant had received a positive recommendation from an FDA advisory panel regarding ezogabine. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee had reviewed the safety and efficacy of the drug and voted unanimously in favor of ezogabine’s efficacy for the treatment of partial-onset seizures in adults where other treatments failed. However, later during the month, the FDA extended the review date for the candidate by three months. Approved in the EU Meanwhile, Glaxo and Valeant announced that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/26/gsk-glaxosmithkline-and-valeant-pharmaceuticals-respond-to-crl-from-fda/72377/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck in Joint Venture with Sun Pharma</title>
		<link>http://www.stockbloghub.com/2011/04/13/mrk-merck-in-joint-venture-with-sun-pharma/71361</link>
		<comments>http://www.stockbloghub.com/2011/04/13/mrk-merck-in-joint-venture-with-sun-pharma/71361#comments</comments>
		<pubDate>Wed, 13 Apr 2011 17:20:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71361</guid>
		<description><![CDATA[Merck &#38; Co., Inc. (MRK) recently announced that it is setting up a joint venture (JV) with Indian multinational pharma company, Sun Pharmaceutical Industries Ltd. The joint venture is for the development, manufacture and commercialization of new combinations and formulations of innovative, branded generics in emerging markets. While financial details of the transaction were not disclosed, the companies said that Sun Pharma’s proprietary platform technologies would be used for the development of products. Meanwhile, Merck will contribute its expertise in clinical development and registration activities. Moreover, Merck will also be bringing its commercial expertise and global reach to the joint venture. Deal in-line with Merck’s Growing Focus on Emerging Markets The joint venture is in-line with Merck’s growing focus on emerging markets. The company has been working on growing its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/mrk-merck-in-joint-venture-with-sun-pharma/71361/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Signs IP Deal with NYU</title>
		<link>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403</link>
		<comments>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403#comments</comments>
		<pubDate>Mon, 11 Apr 2011 03:01:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70403</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced that it has received an exclusive license from the New York University (NYU) for intellectual property covering therapeutic uses of miR-33a and miR-33b to treat diseases such as atherosclerosis and metabolic syndrome. The license was obtained by Regulus Therapeutics Inc., a joint venture company formed by Alnylam in collaboration with Isis Pharmaceuticals (ISIS). In addition to the latest license, Regulus also owns fundamental patent rights related to miR-33a and miR-33b. Atherosclerosis refers to a condition in which the build-up of fatty substances like cholesterol results in the thickening of artery walls. The build-up results in the formation of atherosclerotic lesions or plaques that can slow down or stop the blood flow, ultimately causing myocardial infarction or stroke. Scientist at Regulus and NYU discovered that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Retains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654</link>
		<comments>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:27:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70654</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments and royalties. Isis Pharma has partnership agreements with leading pharmaceuticals companies like Genzyme (GENZ) and GlaxoSmithKline (GSK) among others. Isis Pharma also has a collaboration agreement with biotech company, Alnylam Pharmaceuticals (ALNY). Both companies have joined hands to form Regulus Therapeutics, Inc., a company that is focused on microRNA (mRNA) therapeutics. Isis Pharma focuses its research and development efforts primarily on cardiovascular, metabolic and neurodegenerative diseases and cancer while its partners are involved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GSK) Company News for April 08, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/08/gsk-company-news-for-april-08-2011-corporate-summary/71030</link>
		<comments>http://www.stockbloghub.com/2011/04/08/gsk-company-news-for-april-08-2011-corporate-summary/71030#comments</comments>
		<pubDate>Fri, 08 Apr 2011 17:21:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BBBY]]></category>
		<category><![CDATA[Bed Bath & Beyond Inc.]]></category>
		<category><![CDATA[Coinstar Inc.]]></category>
		<category><![CDATA[Constellation Brands Inc.]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[CSTR]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[Pier 1 Imports Inc.]]></category>
		<category><![CDATA[PIR]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[STZ]]></category>
		<category><![CDATA[Xenoport Inc]]></category>
		<category><![CDATA[XNPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71030</guid>
		<description><![CDATA[• Bed Bath &#38; Beyond Inc.’s (NASDAQ:BBBY) shares rose 10.5% a day after the retailer projected earnings ahead of Wall Street’s expectations for the fiscal year ending in Feb. 2012 • Drug developer Immunogen Inc. (NASDAQ:IMGN) reported positive results from a mid-stage study of its breast-cancer treatment • Home-furnishing retailer Pier 1 Imports Inc (NYSE:PIR) reported better-than-expected profit and sales for the fourth quarter and announced plans to buy back up to $100 million in stock • Late Wednesday, XenoPort Inc. (NASDAQ:XNPT) and GlaxoSmithKline PLC (GSK) announced that they had received regulatory approval for a drug to treat restless-legs syndrome • Citigroup analysts added semiconductor equipment maker, Lam Research Corp (NASDAQ:LRCX) to the brokerage’s conviction sell list • Wine and spirits maker Constellation Brands (NYSE:STZ) forecasts its full-year profit above the Street&#8217;s view and announced a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/08/gsk-company-news-for-april-08-2011-corporate-summary/71030/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus&#8217; Qnexa Weight Loss Candidate Reports Encouraging Study Data</title>
		<link>http://www.stockbloghub.com/2011/04/07/vvus-vivus-qnexa-weight-loss-candidate-reports-encouraging-study-data/70861</link>
		<comments>http://www.stockbloghub.com/2011/04/07/vvus-vivus-qnexa-weight-loss-candidate-reports-encouraging-study-data/70861#comments</comments>
		<pubDate>Thu, 07 Apr 2011 14:09:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70861</guid>
		<description><![CDATA[Vivus, Inc. (VVUS) recently reported positive data from the SEQUEL study on its weight loss candidate, Qnexa. The 52-week SEQUEL study included 675 obese/overweight patients, who had two or more weight-related co-morbidities and an average baseline body mass index (BMI) of 36.1. SEQUEL is an extension study of patients who completed the 56-week CONQUER study. The study data demonstrated a reduction in blood pressure and the need to use antihypertensive medications, along with improved lipid levels. The improvement in lipid levels resulted from significant weight loss in patients treated with Qnexa for two years as compared to those in the placebo arm. We note that Vivus is evaluating Qnexa as a potential treatment for weight loss, type II diabetes and obstructive sleep apnea. The candidate is in mid-stage trials for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/vvus-vivus-qnexa-weight-loss-candidate-reports-encouraging-study-data/70861/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly&#8217;s Axiron Testosterone Deficiency Drug Launched in the U.S.</title>
		<link>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638</link>
		<comments>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638#comments</comments>
		<pubDate>Tue, 05 Apr 2011 15:52:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70638</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Axiron Rights Acquired in March 2010 Eli Lilly acquired exclusive worldwide rights from Australian company, Acrux, to commercialize Axiron in March 2010. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. The FDA approval of Axiron triggered a milestone payment of $87 million from Eli Lilly. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. Men’s Health Portfolio ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(THRX) Theravance Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204</link>
		<comments>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204#comments</comments>
		<pubDate>Sat, 02 Apr 2011 15:18:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Theravance Inc]]></category>
		<category><![CDATA[THRX]]></category>
		<category><![CDATA[ViroPharma Inc]]></category>
		<category><![CDATA[VPHM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70204</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Theravance, Inc. (THRX) with a target price of $25.00 after the company&#8217;s fourth quarter and fiscal year 2010 financial results. Theravance’s fourth quarter 2010 loss per share of 25 cents was narrower than both the Zacks Consensus Estimate for a loss of 28 cents and the year-ago loss of 35 cents per share. The earnings improvement was driven by a better top-line performance and lower research and development costs. Revenue at Theravance increased more than 80% over the prior year to $6.9 million. Revenue was also slightly above the Zacks Consensus Revenue Estimate of $6 million. Theravance has active collaborations with GlaxoSmithKline (GSK) for the Relovair, LAMA/LABA (also called 719/VI) and MABA programs. The Relovair program holds the biggest potential in the company’s pipeline, which ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/02/thrx-theravance-analyst-maintains-neutral-on-shares/70204/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CMLS) Company News for March 11, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/03/11/cmls-company-news-for-march-11-2011-corporate-summary/68582</link>
		<comments>http://www.stockbloghub.com/2011/03/11/cmls-company-news-for-march-11-2011-corporate-summary/68582#comments</comments>
		<pubDate>Fri, 11 Mar 2011 17:45:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Broadcasting - Radio]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[CMLS]]></category>
		<category><![CDATA[Cumulus Media Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GMCR]]></category>
		<category><![CDATA[Green Mountain Coffee Roasters Inc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[IRM]]></category>
		<category><![CDATA[Iron Mountain Inc]]></category>
		<category><![CDATA[LSI]]></category>
		<category><![CDATA[LSI Corporation]]></category>
		<category><![CDATA[National Semiconductor Corporation]]></category>
		<category><![CDATA[NetApp Inc.]]></category>
		<category><![CDATA[NSM]]></category>
		<category><![CDATA[NTAP]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[Semtech Corporation]]></category>
		<category><![CDATA[SIGA]]></category>
		<category><![CDATA[SIGA Technologies Inc]]></category>
		<category><![CDATA[SMTC]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68582</guid>
		<description><![CDATA[• Cumulus Media (NASDAQ:CMLS) reported that it has entered into a merger agreement to acquire all the outstanding common stock and warrants of Citadel Broadcasting Corp for $37 per share • Starbucks (NASDAQ:SBUX) and Green Mountain Coffee Roasters (NASDAQ:GMCR) have entered into a strategic relationship for the manufacturing, marketing, distribution and sale of Starbucks and Tazo tea branded K-Cup portion packs for use in the Keurig single-cup brewing system • National Semiconductor (NYSE:NSM) reported Q3 EPS of $0.24, in line with the Zacks Consensus Estimate. Revenues for the quarter fell 12% year-over-year to $343.9 million, lower than the Zacks Consensus Estimate of $352.0 million • Biotech company SIGA Technologies Inc (NASDAQ:SIGA) reported a fourth quarter operating loss of $4.2 million • Late Wednesday NetApp Inc (NASDAQ:NTAP) announced its plans to buy LSI Corporation’s (NYSE:LSI) external ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/11/cmls-company-news-for-march-11-2011-corporate-summary/68582/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRX) Valeant Pharmaceuticals International&#8217;s Sales Benefit Post Merger</title>
		<link>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808</link>
		<comments>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808#comments</comments>
		<pubDate>Mon, 07 Mar 2011 18:03:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67808</guid>
		<description><![CDATA[Valeant Pharmaceuticals International‘s (VRX) fourth quarter 2010 earnings of 46 cents per share missed the Zacks Consensus Estimate by a cent and was 45.2% below the year-ago earnings of 84 cents per share. Revenues for the quarter increased 102.7% year over year to $514.6 million, in line with the Zacks Consensus. While fourth quarter earnings were within the company’s guidance range of 44 cents to 48 cents per share, revenues were slightly above the guidance of $500 million. Earnings in 2010 declined 19.3% year over year to $1.97 per share, nevertheless beating the Zacks Consensus Estimate of $1.34. Revenues, which saw an increase of 44.0% to $1.18 billion, beat the Zacks Consensus Estimate of $1.15 billion. The increase in revenues was primarily due to the September 2010 merger of Valeant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/07/vrx-valeant-pharmaceuticals-internationals-sales-benefit-post-merger/67808/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharmaceutical Industry Outlook &#8211; March 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917</link>
		<comments>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917#comments</comments>
		<pubDate>Thu, 03 Mar 2011 01:14:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MannKind Corporation]]></category>
		<category><![CDATA[MNKD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67917</guid>
		<description><![CDATA[The pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. According to IMS Health, this is the main reason global pharmaceutical market growth will be restricted to the mid-single digits (5-8%) through 2014. Over the next five years, products that currently generate more than $142 billion in sales are expected to face generic competition, including Lipitor, Plavix and Zyprexa. In fact, 2011 itself will see products worth more than $30 billion losing patent protection. This includes products like Lipitor, Plavix, Zyprexa and Levaquin. These products generated more than $15 billion in sales in 2010. The effect of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/02/jnj-pharmaceutical-industry-outlook-march-2011-industry-outlook/67917/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Company News for January 18, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/01/19/aapl-company-news-for-january-18-2011-corporate-summary/65300</link>
		<comments>http://www.stockbloghub.com/2011/01/19/aapl-company-news-for-january-18-2011-corporate-summary/65300#comments</comments>
		<pubDate>Wed, 19 Jan 2011 23:12:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HUM]]></category>
		<category><![CDATA[Humana Inc.]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[SBIB]]></category>
		<category><![CDATA[Sterling Bancshares Inc]]></category>
		<category><![CDATA[Symantec Corporation]]></category>
		<category><![CDATA[SYMC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=65300</guid>
		<description><![CDATA[• Comerica (NYSE:CMA) has plans to purchase Sterling Bancshares (NASDAQ:SBIB) for $1.03 billion for a deal worth $10 per share • GlaxoSmithKline (NYSE:GSK) reported charges of $3.4 billion in the fourth quarter to settle lawsuits and fines from earlier sales practices, mostly because of its diabetes drug Avandia • Boeing (NYSE:BA) reported a resumption of certified testing of its long-delayed 787 Dreamliner on Monday, almost three years behind its expected schedule • Delta Airlines (NYSE:DAL) has reported airlines earnings numbers, with a fourth quarter showing of $0.19, below the Zacks Consensus Estimate of $0.26, on revenues of $7.8 billion ahead of the Zacks Consensus Estimate of $7.687 billion • According to Piper Jaffray (NYSE:PJC), weakness in Apple’s  (NASDAQ:AAPL) shares due to absence of CEO Steve Jobs&#8217; because of health related issues offers a fantastic buying ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/01/19/aapl-company-news-for-january-18-2011-corporate-summary/65300/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VVUS) Vivus Seeks EU Nod for Qnexa</title>
		<link>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722</link>
		<comments>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722#comments</comments>
		<pubDate>Tue, 28 Dec 2010 06:46:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ARNA]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[OREX]]></category>
		<category><![CDATA[Orexigen Therapeutics Inc.]]></category>
		<category><![CDATA[VIVUS Inc]]></category>
		<category><![CDATA[VVUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=63722</guid>
		<description><![CDATA[Vivus, Inc. (VVUS) recently announced that it has filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking approval for Qnexa. The company is looking to get Qnexa approved in the EU for the treatment of obesity (in conjunction with a mildly hypocaloric diet), including weight loss and maintenance of weight loss. Qnexa’s approval would be a major positive for Vivus. The obesity market represents huge commercial potential for Vivus. Obesity is a worldwide epidemic and is estimated to affect about 150 million adults in the EU. A smooth review process could result in Qnexa receiving EU approval in late 2011. Currently available treatments for obesity include orlistat, sold by Roche (RHHBY) as Xenical and by GlaxoSmithKline (GSK) as Alli (available over-the-counter). A commercially available prescription product ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/27/vvus-vivus-seeks-eu-nod-for-qnexa/63722/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly and Company Gets FDA Approval of Axiron</title>
		<link>http://www.stockbloghub.com/2010/12/19/lly-eli-lilly-and-company-gets-fda-approval-of-axiron/60396</link>
		<comments>http://www.stockbloghub.com/2010/12/19/lly-eli-lilly-and-company-gets-fda-approval-of-axiron/60396#comments</comments>
		<pubDate>Sun, 19 Dec 2010 23:24:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60396</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Eli Lilly acquired exclusive worldwide rights to commercialize Axiron earlier this year. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. With Axiron having gained FDA approval, Acrux now stands to receive a milestone payment of $87 million from Eli Lilly. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. The addition of Axiron has helped boost Eli Lilly’s ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/19/lly-eli-lilly-and-company-gets-fda-approval-of-axiron/60396/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ACN) Accenture Announces Plan to Acquire CRM Software Firm CAS Computer</title>
		<link>http://www.stockbloghub.com/2010/12/14/acn-accenture-announces-plan-to-acquire-crm-software-firm-cas-computer/60253</link>
		<comments>http://www.stockbloghub.com/2010/12/14/acn-accenture-announces-plan-to-acquire-crm-software-firm-cas-computer/60253#comments</comments>
		<pubDate>Tue, 14 Dec 2010 21:00:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Management Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Accenture Limited]]></category>
		<category><![CDATA[ACN]]></category>
		<category><![CDATA[Campbell Soup Company]]></category>
		<category><![CDATA[CPB]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Molson Coors Brewing Company]]></category>
		<category><![CDATA[RAI]]></category>
		<category><![CDATA[Reynolds American Inc.]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[TAP]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=60253</guid>
		<description><![CDATA[Technology outsourcing and consulting major Accenture plc (ACN) recently announced its intention to acquire Germany-based customer relationship management (CRM) and mobility software provider CAS Computer AG. The acquisition is expected to close by the end of January 2011. Financial terms of the deal were not disclosed. CAS Computer provides software applications that facilitate organizations to better manage their trade promotions, retail executions and customer service. The company’s services are specifically targeted at organizations operating in the consumer products industry. CAS Computer’s client base includes leading brand manufacturers such as Campbell Soup Company (CPB), Coca-Cola Company (KO), GlaxoSmithKline plc (GSK), Henkel, Molson Coors Brewing Company (TAP), Nestlé and Reynolds American, Inc. (RAI). The acquisition will make Accenture’s CRM service suite more insightful. Accenture will integrate the new unit under its software ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/14/acn-accenture-announces-plan-to-acquire-crm-software-firm-cas-computer/60253/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Beats Earnings Expectations &#8211; Increases Earnings Outlook</title>
		<link>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674</link>
		<comments>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:52:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Impax Laboratories Inc]]></category>
		<category><![CDATA[IPXL]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58674</guid>
		<description><![CDATA[Shire plc (SHPGY) posted earnings of $1.16 per American Depositary Share (ADS) during the third quarter of 2010, beating the Zacks Consensus Estimate of 98 cents and the year-ago earnings of 49 cents per ADS. Higher revenues accounted for the strong performance. Revenues Quarterly revenues increased 31% year over year to $874 million, well above the Zacks Consensus Estimate of $847 million. Increased product sales and higher royalties helped boost revenues. Product sales went up 32% to $794 million, while royalties increased 27% to $76.5 million. Royalty revenue mainly comprises income earned on the sale of the authorized generic version of Adderall XR, 3TC and Zeffix. During the third quarter, Shire received royalties from Impax Laboratories Inc. (IPXL) for Adderall XR and from GlaxoSmithKline plc (GSK) for 3TC and Zeffix. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/shpgy-shire-beats-earnings-expectations-increases-earnings-outlook/58674/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

